Intranasal CO2 for Allergic Rhinitis

NCT ID: NCT00618410

Last Updated: 2014-01-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2008-09-30

Brief Summary

The purpose of this study is to better understand the way in which CO2 (carbon dioxide) affects the symptoms of allergic rhinitis or hayfever.

Our intent is to determine if CO2 has an effect on nasal challenge with antigen as a predictor of whether it will have a beneficial effect on the treatment of seasonal allergic rhinitis.

Detailed Description

Study design: We performed a randomized, two-way crossover study in subjects with seasonal allergic rhinitis out of season. Subjects came to the Nasal Physiology Laboratory for screening, where they completed an allergy questionnaire and underwent skin-prick testing for confirmation of a grass or ragweed allergy. The skin test included positive and negative controls and the results were graded compared with the controls as 1+ to 4+ (1+: wheal larger than negative control and smaller than positive control; 2+: wheal 5-7 mm; 3+: wheal 7-10 mm; 4+: any reaction with a wheal >10 mm or pronounced pseudopodia). Subjects with positive skin test (between 2+ and 4+) and a positive history of allergic symptoms during the relevant seasons then underwent a screening nasal challenge with either grass or ragweed allergen. Subjects who passed the screening challenge (twofold increase in either ipsilateral or contralateral nasal secretions after allergen challenge compared with diluent) had a 2-week washout period and returned to the laboratory, where they were randomized to receive intranasal treatment with either CO2 or no treatment. Thirty minutes after treatment, subjects underwent a nasal challenge with allergen. Seven subjects were challenged with ragweed and five subjects were challenged with grass. Subjects had another 2-weeks washout period and were then crossed over to the other treatment followed by a similar challenge. Previous work in our laboratory using a similar challenge system showed that allergen-induced inflammatory changes are back to baseline 2 weeks after the challenge.

Subjects: Twelve subjects participated. Subjects were studied outside their allergy season. All subjects were healthy except for mild asthma requiring only as-needed bronchodilators. They were not on any medications and had not received antihistamines or leukotriene receptor antagonists for at least 1 week and intranasal steroids for at least 1 month before enrollment and for the duration of the study.

Treatment: CO2 was applied for 10 seconds in each nostril using a special applicator (plastic tight-seal nosepiece) attached to a CO2 canister and a flow control valve. It was delivered at a flow rate of 0.5 standard L/min with the mouth open to prevent inhalation. Thus, for 20-second duration of administration, the total dose of CO2 delivered was 167 mL. The amount of CO2 delivered to the mucosa is unknown. The no-treatment arm involved placement of the device but no gas was delivered. Therefore, neither the subjects nor the investigators were blinded to the treatment administered. The no-treatment arm did not involve the delivery of air without CO2 to the nose because we were concerned that blowing dry air into the nose might cause a mucosal reaction that could confound the results. We have previously shown that cold, dry air challenges create a hyperosmolar environment, triggers mast cell activation, and induces a nasonasal reaction.7 Thus, because our primary outcome was the objective measure of the nasonasal reflex, we avoided this possibility.

Nasal Challenge: The subjects were allowed 15 minutes to acclimatize to the laboratory environment before challenge. Baseline sneezes reflecting the 15 minutes of acclimatization and nasal and eye symptoms were recorded followed by collection of a nasal scraping for quantitation of eosinophils in nasal secretions. Sneezes were recorded by the subjects during each of the assessed intervals of the challenge protocol. The subjects were reminded to keep track of the number of sneezes by the research coordinator who was present for the duration of the challenges. Intranasal CO2 or sham was then applied for 10 seconds to each nostril. Thirty minutes later, sneezes and symptoms were recorded again, to reflect the 30-minute time period, and nasal challenge was initiated. Because we were interested in evaluating the effect of the treatment on allergen-induced nasal reflexes, we used filter paper disks to perform the challenges and monitor the secretory response as previously described.

Briefly, 8-mm filter paper disks (Shandon, Inc., Pittsburgh, PA) were used for both nasal challenge and collection of resultant secretions. They were placed on the anterior nasal septum, beyond the mucocutaneous junction, under direct vision using a nasal speculum, forceps, and a headlight. Fifty microliters of challenge solutions were placed on the disks, which were then applied to the nasal septum for 1 minute. Thirty seconds after removal, two preweighed filter paper disks were placed on both sides of the nasal septum for 30 seconds, collecting nasal secretions from the challenge site (ipsilateral) and the contralateral nostril. These disks were then immediately placed back into microtubes and weighed. The difference in their weight before and after challenge was the weight of produced nasal secretions, which was recorded in milligrams. Ten minutes after each challenge, the number of sneezes as well as symptoms on each side were recorded by the subjects reflective of the 10-minute interval The first challenge was performed using phenol-buffered saline, the diluent for the allergen extracts, and this was followed by 2 increasing doses of grass or ragweed allergen. The time from treatment administration to the first allergen challenge was approximately 40 minutes and to the second allergen challenge, 50 minutes. The amount of allergen applied on the paper disks for challenge were 333 and 1000 BAU (bioequivalent allergy unit) of grass allergen extract (Hollister-Stier, Spokane, WA) or 50 microliters of ragweed antigen extract at concentrations of 1:666 and 1:200 w/v (Hollister-Stier). The subjects came back to the laboratory 24 hours later and underwent a scraping of their nasal secretions to evaluate for eosinophil influx.

Conditions

Allergic Rhinitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: DOUBLE

Study Groups

Carbon dioxide

nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge

Group Type: ACTIVE_COMPARATOR

Carbon dioxide, USP

Intervention Type: DEVICE

Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril

Placebo

nasal placebo administered 30 minutes prior to nasal challenge

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Nasal placebo

Interventions

Carbon dioxide, USP

Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril

Intervention Type: DEVICE

Placebo

Nasal placebo

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Males and females between 18 and 45 years of age.

2. History of grass and/or ragweed allergic rhinitis.

3. Positive skin test to grass and/or ragweed antigen.

4. Positive response to screening nasal challenge.

Exclusion Criteria

1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.

2. Pregnant or lactating women.

3. Upper respiratory infection within 14 days of study start.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Capnia, Inc.

INDUSTRY

Sponsor Role: collaborator

University of Chicago

OTHER

Sponsor Role: lead

Responsible Party

Robert Naclerio

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Robert Naclerio, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

University of Chicago

Chicago, Illinois, United States

Countries

United States

References

Baroody FM, Gavanescu L, Wang JH, DeTineo M, Naclerio RM. The effect of intranasal carbon dioxide on the acute response to nasal challenge with allergen. Allergy Asthma Proc. 2011 May-Jun;32(3):206-12. doi: 10.2500/aap.2011.32.3442.

Reference Type: RESULT

PMID: 21703101 (View on PubMed)

Other Identifiers

15835A

Identifier Type: -

Identifier Source: org_study_id